Within the CaPACITY program, we initiated a pilot study investigating the following: (1) Detection of HHV6 DNA in the heart of HF patients and its association with myocarditis, (2) the spontaneous course of HHV6 DNA-associated myocarditis, (3) the regulation of the NLRP3 inflammasome pathway and structural protein signatures on EMB level, and (4) the safety and effectiveness of immunosuppression in HHV6 DNA-positive patients with cardiac inflammation. This evidence concerns the gene NLRP3 and myocarditis.